A landmark study published this week has revealed that experimental treatments for deadly pathogens may, in fact, require conducting experiments on those very pathogens. The finding, which examined 847 biomedical research partnerships over the past decade, appears to suggest that the process of developing untested therapies involves testing therapies that have not yet been tested.

"What makes this finding particularly striking is the apparent correlation between experimental status and the need for experimentation," said Dr. Miranda Kowalski, Professor of Therapeutic Uncertainty at Johns Hopkins School of Speculative Medicine. "We're seeing a consistent pattern where treatments labeled as 'experimental' seem to require actual experiments, which raises profound questions about our understanding of what experiments are for."

The study, which is already drawing attention from researchers not involved in the study, found that 94% of experimental treatments had not been previously tested, while an additional 78% involved compounds that researchers described as "we're not entirely sure what this will do." Dr. Hassan Al-Rashid, Chair of Molecular Optimism at the CDC, told reporters that the implications could be far-reaching, particularly for diseases that require treatment.

"The real question," Al-Rashid noted while reviewing the data, "is whether we're prepared for a future where medical breakthroughs consistently involve attempting things we haven't attempted before."